CA-AMBARELLA
21.6.2021 11:02:09 CEST | Business Wire | Press release
Ambarella, Inc. (NASDAQ: AMBA), an AI vision silicon company, today announced the expansion of its AI vision SoC portfolio with the new CV5S and CV52S security families. Based on the CVflow® architecture and advanced 5nm process technology, the new SoCs support simultaneous 4K encoding and advanced AI processing in a single low-power design, which provides industry-leading edge AI SoC performance per watt. The CV5S family is ideal for security camera applications that require multiple sensors for 360-degree coverage, over a wide area and with a long range, such as outdoor city environments or large buildings. The CV52S family is designed for single-sensor security cameras with advanced AI performance that need to more clearly identify individuals or objects in a scene, including faces and license plate numbers over long distances, such as ITS traffic cameras.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210621005178/en/
“Security system designers desire higher resolutions, increasing channel counts, and ever faster and more ubiquitous AI capabilities,” explained John Lorenz, senior technology & market analyst, computing at Yole Développement (Yole). “Ambarella’s newest AI vision SoCs for security, the CV5S and CV52S, are competitive solutions for meeting the growing demands of the security IC sector, which we forecast to exceed $4 billion by 2025, with two-thirds of that being chips with AI capabilities.” (1)
The new CV5S SoC family supports multi-imager camera designs and can simultaneously process and encode four imager channels of up to 8MP, or 4K resolution, each at 30 frames per second (fps), while performing advanced AI on each 4K imager. These SoCs double the encoding resolution and memory bandwidth while consuming 30% less power than Ambarella’s prior generation.
The new CV52S SoC family targets single-sensor security cameras and supports 4K resolution at 60fps, while providing 4x the AI computer vision performance, 2x the CPU performance and 50% more memory bandwidth than its predecessors. This increase in neural network (NN) performance enables more AI processing to be performed at the edge, instead of in the cloud.
“The global security industry is rapidly moving to higher 4K resolutions while increasing AI algorithm capabilities, to achieve better recognition of people and objects, along with multiple imagers for a wider field of view and longer range,” said Jerome Gigot, senior director of marketing, Ambarella. “Our new CV5S and CV52S security AI vision SoC families respectively support 4K multi-imager or high-frame-rate 4K single-imager designs with high performance edge AI processing, allowing the development of cameras that do not need to compromise between image resolution and AI processing accuracy.”
In addition to security, there are many other AIoT applications that can take advantage of the high resolution and advanced AI processing provided by these new SoC families. For example, smart cities can leverage high edge AI performance and image resolution for improved traffic management, accident detection and automated speed control, as well as the rapid location of missing and stolen vehicles. Likewise, smart retail operations can use this resolution and advanced AI to better manage product placement, adjust cashier staffing for real-time line management, enhance warehouse product tracking, and provide more actionable intelligence at both the store and corporate levels.
Additional features of the new CV5S and CV52S families include:
- Robust SDK created specifically for the security camera market
- CVflow tools that are compatible across all security families
- Dual Arm® A76 1.6GHz CPUs with 1MB of L3 memory; a 2x performance gain over the prior generation for faster customer applications
- Enhanced ISP with excellent HDR, ISO low-light, dewarping and rotation performance
- On-chip privacy masking to block out a portion of the captured scene
- New PCIe and USB 3.2 interfaces, enabling more complex, multi-chip security system designs than prior generation
- Strong on-chip cybersecurity hardware to ensure secure IP cameras, including secure boot, OTP and Arm TrustZone technology
- Multiple video inputs, with support for up to 14 cameras using MIPI virtual channels
- SLVS-EC interface on the CV5S for reduced system design complexity
- Support for LPDDR4x, LPDDR5 and LPDDR5x DRAM
Availability
The CV5S and CV52S SoC families are expected to be available for sampling in October. For more information, contact Ambarella: https://www.ambarella.com/contact-us/ .
About Ambarella
Ambarella’s products are used in a wide variety of human and computer vision applications, including video security, advanced driver assistance systems (ADAS), electronic mirror, drive recorder, driver/cabin monitoring, autonomous driving and robotics applications. Ambarella’s low-power systems on chip (SoCs) offer high-resolution video compression, advanced image processing and powerful deep neural network processing to enable intelligent cameras to extract valuable data from high-resolution video streams. For more information, please visit www.ambarella.com
All brand names, product names, or trademarks belong to their respective holders. Ambarella reserves the right to alter product and service offerings, specifications, and pricing at any time without notice. © 2021 Ambarella. All rights reserved.
1. Source: Cameras and computing for surveillance and security report , Yole Développement, 2020
View source version on businesswire.com: https://www.businesswire.com/news/home/20210621005178/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
